Wanbury Ltd

Wanbury Ltd – Trading Window Closure

AGM details

• Held on Sep 24, 2026 at 11:30 am via VC/OAVM.
• Remote e-voting window: Sep 21–23, 2026.

Key resolutions

• Ordinary: Adopt Audited Financial Statements for FY ended 31 Mar 2026.
• Ordinary: Re-appoint director by rotation (K Chandran).
• Ordinary: Ratify remuneration of Cost Auditor ABK & Associates for 2026-27.
• Special: Re-appoint Mohan Kumar Rayana as Whole-time Director beyond age 70.

Voting results

• Resolution 1 passed; majority in favour; minority opposed.
• Resolution 2 passed; majority in favour; minority opposed.
• Resolution 3 passed; majority in favour; minority opposed.
• Resolution 4 passed; majority in favour; minority opposed.

Director changes

• K Chandran re-appointed by rotation.
• Mohan Kumar Rayana re-appointed as Whole-time Director beyond age 70.

Auditor remuneration

• Cost Auditor ABK & Associates remuneration ratified for FY 2026-27.

Cost Auditor appointment

• Appointment and ratification of remuneration payable to ABK & Associates, Cost Auditor, for FY 2026-27.

Whole-time Director re-appointment

• Re-appointment of Mohan Kumar Rayana as Whole-time Director; continuation beyond age 70, 21 August 2026–20 August 2031.

AGM details and outcome

• AGM held on 24 September 2026 at 11:30 AM via VC/OAVM.
• All resolutions put to vote were passed with the requisite majority.

Book closure details

• Book closure: 18 September 2026 to 24 September 2026 (inclusive).
• Purpose: 38th Annual General Meeting of Wanbury Limited.
• AGM date and time: 24 September 2026 at 11:30 A.M. (VC/OAVM).
• Security: equity shares.

Overview & results

• Consolidated revenue from operations: ₹65,026.81 Lakhs.
• Total income: ₹65,120.54 Lakhs; expenses ₹58,779.96 Lakhs.
• PAT after tax: ₹6,613.47 Lakhs; EPS ₹20.55 (basic, pre-exceptional).
• EPS (diluted, pre-exceptional): ₹20.48; EPS (basic, post): ₹19.49.
• Dividend: Board did not declare a dividend for FY2025-26.

Capital structure & equity actions

• Warrants converted to equity; share capital up by ₹200 Lakhs.
• Equity share premium increased by ₹22,000 Lakhs.
• ESOPs: 3,34,000 options granted; 1,68,900 exercised; 4,11,750 outstanding.
• Total borrowings ₹21,545.03 Lakhs; net debt ₹21,383.87 Lakhs after cash ₹161.16 Lakhs.
• Debt-Equity ratio improved to 1.57x from 3.02x.

Major developments & regulatory

• Rise with SAP S/4HANA ERP live from Oct 3, 2025.
• ERP rollout to boost planning, visibility and process integration.
• API regulatory wins: US FDA, ANVISA; MFDS inspections cleared.
• Sertraline Form II approved in Brazil; Form I already approved.
• Wanbury C-RED liposomal iron launched regionally; pan-India rollout planned.

Operations & geography

• Geographic revenue: India ₹17,448.68 Lakhs; Brazil ₹9,070.85; Others ₹37,871.10.
• Export revenue contributes a large share of API revenue; EU/US/Brazil key markets.

Audit, governance & risk

• Board meetings: Seven in FY2025-26; independent directors meetings held.
• Secretarial audit flagged board composition & committee formation; penalties paid; resolved.
• Audit & Risk Committees in place; whistle-blower mechanism active; no fraud reported.

CSR, ESG & sustainability

• CSR spend ₹8.00 Lakhs; shortfall ₹25.36 Lakhs.
• CSR initiatives include education, healthcare, women empowerment, and water conservation.

Cash flows & liquidity

• Operating cash flow ₹3,153.01 Lakhs; financing cash flow ₹2,242.45 Lakhs.
• Net cash at year-end ₹161.16 Lakhs; liquidity supported by ERP & reforms.

Key disclosures

• EDQM approved Wanbury's Rivaroxaban API, supporting EU and CEP markets.
• US FDA DMF clearance obtained for Paroxetine HCl and Metformin HCl.
• ANDA review is ongoing for multiple Wanbury customers.